Clot Burst Pressure (CBP) Measurement Device

Description:

Researchers from UTHealth designed a device for developing a clot burst pressure (CBP) which can be used for direct measurement of the pressure required to dislodge a clot. More particularly, this measurement can distinguish between thrombi of hypo- and hypercoagulable states by observing differences in the CBP of conditioned groups compared to control CBP. This has the potential to be applied for a better understanding of trauma pathophysiology, thus can help direct acute care to reduce mortality rates and associated morbidities due to inappropriate resusitation.

Background

Trauma is the leading cause of death in the United States for individuals under 46. Hemorrhagic shock accounts for up to 40% of all trauma deaths and is responsible for a lethal triad of trauma.

Due to rapid turnover of clotting factors, newly formed clots are generated in a hypocoagulable and hyperfibrinolytic state. A better understanding of clot integrity can help optimize the use of resuscitation strategies, such as permissive hypotension without disrupting desired coagulation.

Discovery

Researchers at UTHealth have developed and tested a clot burst pressure (CBP) measurement device that allows clinicians to directly measure the pressure required to dislodge a clot, and developed a standardized assay used to test the impact that combinations and permutations of individual resuscitation products and clotting factors have on a patient in a clinically relevant parameter: i.e., mmHg.

Benefits/Technology Advantages

  • This CBP device can allow for rapid testing of clot strength in a parameter, burst pressure, not seen in existing devices such as TEG;
  • This CBP device can distinguish between thrombi of hypo- and hypercoagulable states by observing differences in the CBP of conditioned groups compared to control CBP.

Potential Applications

  • This CBP device can be used as point of care to directly measure the pressure required to dislodge a clot and is simple to manufacture and perform, low-cost, and requires a much smaller volume of blood than other devices, such as TEG.
  • This CBP device can be used to better understand trauma pathophysiology with the use of blood from trauma patients, which can help direct acute care to reduce mortality rates and associated morbidities.

Intellectual Property Status

  • U.S. provisional patent application filed
  • Available for licensing

Stage of Development

Prototype has been developed and tested

Associated Publications

Design and Development of a Clot Burst Pressure Device to Investigate Resuscitation StrategiesJ. Surg. Res., Volume 291, November 2023, Pages 646-652

About the Principal Investigators

Dr. Brijesh S. Gill, MD, FACS

Professor of McGovern Medical School at UTHealth

Dr. Charles S. Cox, Jr, MD, FACS

George & Cynthia Mitchell Distinguished Chair in Neurosciences at UTHealth;

Director of Program in Children's Regenerative Medicine;

Co-Director of Texas Trauma Institute

 

UTHealth Ref. No: 2023-0017

Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
Category(s):
Medical Devices
Trauma
For Information, Contact:
Xiaoyan Wang
Technology Commercialization Analyst
University of Texas Health Science Center At Houston
Xiaoyan.Wang@uth.tmc.edu
Inventors:
Keywords:
© 2024. All Rights Reserved. Powered by Inteum